# Jose R Arribas

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 210 papers | 9,221 citations | 52 h-index | 91 g-index |
| 242 ext. papers | 10,998 ext. citations | 6.9 avg, IF | 5.65 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 210 | Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. *New England Journal of Medicine*, **2006**, 354, 251-60 | 59.2 | 742 |
| 209 | Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. *New England Journal of Medicine*, **2002**, 346, 2039-46 | 59.2 | 561 |
| 208 | Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. *Clinical Infectious Diseases*, **2010**, 51, 963-72 | 11.6 | 327 |
| 207 | Clinical Management of Ebola Virus Disease in the United States and Europe. *New England Journal of Medicine*, **2016**, 374, 636-46 | 59.2 | 246 |
| 206 | Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. *Lancet Infectious Diseases, The*, **2012**, 12, 111-8 | 25.5 | 212 |
| 205 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. *Lancet Infectious Diseases, The*, **2016**, 16, 43-52 | 25.5 | 211 |
| 204 | Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. *American Journal of Public Health*, **2010**, 100, 1896-903 | 5.1 | 202 |
| 203 | Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2006**, 43, 535-40 | 3.1 | 199 |
| 202 | Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2008**, 47, 74-8 | 3.1 | 184 |
| 201 | Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. *Lancet, The*, **2019**, 393, 143-155 | 40 | 175 |
| 200 | Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study. *Annals of Internal Medicine*, **2020**, 173, 536-541 | 8 | 159 |
| 199 | Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. *Lancet Infectious Diseases, The*, **2011**, 11, 907-15 | 25.5 | 155 |
| 198 | Cytomegalovirus encephalitis. *Annals of Internal Medicine*, **1996**, 125, 577-87 | 8 | 153 |
| 197 | Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. *Clinical Infectious Diseases*, **2002**, 34, 838-46 | 11.6 | 152 |
| 196 | The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. *Aids*, **2010**, 24, 223-30 | 3.5 | 148 |
| 195 | Assessment of second-line antiretroviral regimens for HIV therapy in Africa. *New England Journal of Medicine*, **2014**, 371, 234-47 | 59.2 | 147 |
| 194 | A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 146 |

| | | | |
|---|---|---|---|
| 193 | Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. *Aids* , **2003**, 17, 1023-8 | 3.5 | 143 |
| 192 | Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2005**, 40, 280-7 | 3.1 | 139 |
| 191 | Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. *Lancet, The*, **2014**, 384, 1942-51 | 40 | 136 |
| 190 | Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet, The*, **2021**, 398, 121-130 | 40 | 133 |
| 189 | Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2016**, 71, 530-7 | 3.1 | 132 |
| 188 | Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. | 25.5 | 120 |
| 187 | Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. *Lancet Infectious Diseases, The*, **2015**, 15, 785-92 | 25.5 | 111 |
| 186 | Probable sexual transmission of Zika virus from a vasectomised man. *Lancet Infectious Diseases, The* , **2016**, 16, 1107 | 25.5 | 110 |
| 185 | Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. *Aids*, **2008**, 22, F1-9 | 3.5 | 109 |
| 184 | Autochthonous Crimean-Congo Hemorrhagic Fever in Spain. *New England Journal of Medicine*, **2017** , 377, 154-161 | 59.2 | 101 |
| 183 | Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. *Lancet Respiratory Medicine,the*, **2015**, 3, 554-62 | 35.1 | 100 |
| 182 | Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2009**, 51, 147-52 | 3.1 | 96 |
| 181 | Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. *Lancet Infectious Diseases, The*, **2014**, 14, 581-9 | 25.5 | 95 |
| 180 | Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. *Aids*, **2014**, 28, 989-97 | 3.5 | 90 |
| 179 | Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2016**, 72, 58-64 | 3.1 | 89 |
| 178 | Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. *Neurology*, **2014**, 83, 134-41 | 6.5 | 85 |
| 177 | Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. *PLoS ONE*, **2011**, 6, e22003 | 3.7 | 83 |
| 176 | A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. *Journal of Infectious Diseases*, **2008**, 198, 234-40 | 7 | 83 |

| | | | |
|---|---|---|---|
| 175 | Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2017**, 75, 211-218 | 3.1 | 81 |
| 174 | Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. *Lancet HIV,the*, **2018**, 5, e211-e220 | 7.8 | 80 |
| 173 | Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. *AIDS Research and Human Retroviruses*, **2011**, 27, 29-34 | 1.6 | 76 |
| 172 | Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. *Clinical Infectious Diseases*, **2017**, | 11.6 | 71 |
| 171 | Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. *Journal of Antimicrobial Chemotherapy*, **2004**, 53, 540-3 | 5.1 | 70 |
| 170 | Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. *Journal of Antimicrobial Chemotherapy*, **2005**, 55, 800-4 | 5.1 | 69 |
| 169 | Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. *Aids*, **2000**, 14, 979-85 | 3.5 | 67 |
| 168 | Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, | 7.8 | 64 |
| 167 | A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2009**, 51, 290-7 | 3.1 | 62 |
| 166 | Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). *Clinical Microbiology and Infection*, **2021**, 27, 244-252 | 9.5 | 61 |
| 165 | Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. *Aids*, **2019**, 33, 1455-1465 | 3.5 | 60 |
| 164 | Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. *Lancet HIV,the*, **2015**, 2, e464-73 | 7.8 | 60 |
| 163 | The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. *Aids*, **2011**, 25, 899-904 | 3.5 | 56 |
| 162 | Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet HIV,the*, **2019**, 6, e364-e372 | 7.8 | 55 |
| 161 | Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. *Journal of Infectious Diseases*, **2017**, 215, 1789-1798 | 7 | 53 |
| 160 | Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. *HIV Medicine*, **2016**, 17, 358-67 | 2.7 | 53 |
| 159 | 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. *Antiviral Therapy*, **2013**, 18, 905-13 | 1.6 | 52 |
| 158 | Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2020**, 83, 310-318 | 3.1 | 52 |

| | | | |
|---|---|---|---|
| 157 | 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA . *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 1878-85 | 5.1 | 50 |
| 156 | Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. *Aids*, **2001**, 15, 1701-6 | 3.5 | 49 |
| 155 | Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. *Clinical Infectious Diseases*, **2013**, 57, 112-21 | 11.6 | 45 |
| 154 | Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. *Journal of Antimicrobial Chemotherapy*, **2008**, 61, 1359-61 | 5.1 | 45 |
| 153 | Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2004**, 35, 343-50 | 3.1 | 42 |
| 152 | Protease inhibitor monotherapy and the CNS: peace of mind?. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 1954-62 | 5.1 | 40 |
| 151 | Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. *Diagnostic Microbiology and Infectious Disease*, **2008**, 62, 34-43 | 2.9 | 40 |
| 150 | Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. *Clinical Infectious Diseases*, **2014**, 59, 425-34 | 11.6 | 39 |
| 149 | The future of antiretroviral therapy: challenges and needs. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 827-35 | 5.1 | 39 |
| 148 | New filovirus disease classification and nomenclature. *Nature Reviews Microbiology*, **2019**, 17, 261-263 | 22.2 | 38 |
| 147 | Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. *Antiviral Therapy*, **2009**, 14, 195-201 | 1.6 | 38 |
| 146 | Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003. *Acta Obstetricia Et Gynecologica Scandinavica*, **2007**, 86, 409-15 | 3.8 | 37 |
| 145 | Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. *Clinical Infectious Diseases*, **2006**, 43, 79-89 | 11.6 | 36 |
| 144 | Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. *Aids*, **2011**, 25, 1683-90 | 3.5 | 34 |
| 143 | Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature. *International Journal of Infectious Diseases*, **2010**, 14, e522-5 | 10.5 | 32 |
| 142 | Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. *Aids*, **2016**, 30, 251-9 | 3.5 | 29 |
| 141 | Protease inhibitor monotherapy. *Current Opinion in Infectious Diseases*, **2011**, 24, 7-11 | 5.4 | 29 |
| 140 | Advances in antiretroviral therapy. *Current Opinion in HIV and AIDS*, **2013**, 8, 341-9 | 4.2 | 28 |

| | | | |
|---|---|---|---|
| 139 | Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. *Journal of Clinical Pharmacology*, **2006**, 46, 265-74 | 2.9 | 28 |
| 138 | Persistence and infectivity of Zika virus in semen after returning from endemic areas: Report of 5 cases. *Journal of Clinical Virology*, **2017**, 96, 110-115 | 14.5 | 27 |
| 137 | Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. *Aids*, **2015**, 29, 1811-20 | 3.5 | 27 |
| 136 | Hypertension and isolated office hypertension in HIV-infected patients determined by ambulatory blood pressure monitoring: prevalence and risk factors. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2011**, 58, 54-9 | 3.1 | 27 |
| 135 | Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis. *Journal of NeuroVirology*, **1996**, 2, 397-403 | 3.9 | 27 |
| 134 | Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. *Lancet HIV,the*, **2020**, 7, e389-e400 | 7.8 | 27 |
| 133 | The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure. *Journal of Infectious Diseases*, **2017**, 216, S847-S850 | 7 | 26 |
| 132 | A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. *Trials*, **2020**, 21, 466 | 2.8 | 25 |
| 131 | HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. *Aids*, **2009**, 23, 971-5 | 3.5 | 25 |
| 130 | Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. *HIV Clinical Trials*, **2010**, 11, 163-9 | | 25 |
| 129 | Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. *Lancet Infectious Diseases, The*, **2021**, 21, 783-792 | 25.5 | 25 |
| 128 | Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial. *HIV Clinical Trials*, **2013**, 14, 45-50 | | 23 |
| 127 | Causes and consequences of incomplete HIV RNA suppression in clinical trials. *HIV Clinical Trials*, **2009**, 10, 289-98 | | 23 |
| 126 | Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. *Virus Research*, **2016**, 213, 224-229 | 6.4 | 22 |
| 125 | Treatment of Ebola virus disease. *Intensive Care Medicine*, **2015**, 41, 115-7 | 14.5 | 21 |
| 124 | Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. *HIV Clinical Trials*, **2006**, 7, 86-96 | | 21 |
| 123 | Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting. *AIDS Research and Therapy*, **2013**, 10, 3 | 3 | 20 |
| 122 | Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. *PLoS ONE*, **2013**, 8, e69493 | 3.7 | 19 |

| | | | |
|---|---|---|---|
| 121 | Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. *Clinical Infectious Diseases*, **2019**, 68, 597-606 | 11.6 | 18 |
| 120 | Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19 **2022**, 1, | | 18 |
| 119 | High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). *Aids*, **2002**, 16, 1554-6 | 3.5 | 18 |
| 118 | A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals. *Clinical Infectious Diseases*, **2014**, 59, 1627-34 | 11.6 | 17 |
| 117 | Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. *Clinical Infectious Diseases*, **2011**, 52, 662-70 | 11.6 | 17 |
| 116 | Impact of COVID-19 on Madrid hospital system. *Enfermedades Infecciosas Y Microbiología Clínica*, **2021**, 39, 256-257 | 0.9 | 17 |
| 115 | The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL. *Journal of the International AIDS Society*, **2014**, 17, 19525 | 5.4 | 16 |
| 114 | Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. *Journal of the International AIDS Society*, **2014**, 17, 19788 | 5.4 | 16 |
| 113 | Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. *Antiviral Therapy*, **2011**, 16, 59-65 | 1.6 | 16 |
| 112 | Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. *Antiviral Therapy*, **2011**, 16, 725-32 | 1.6 | 16 |
| 111 | The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. *Aids*, **2006**, 20, 2331-5 | 3.5 | 16 |
| 110 | Impact of COVID-19 on Madrid hospital system. *Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )*, **2021**, 39, 256-257 | 0.1 | 16 |
| 109 | Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. *AIDS Research and Human Retroviruses*, **2010**, 26, 747-57 | 1.6 | 15 |
| 108 | Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. *PLoS ONE*, **2019**, 14, e0209911 | 3.7 | 14 |
| 107 | Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **1999**, 22, 308-9 | 3.1 | 14 |
| 106 | Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). *EBioMedicine*, **2020**, 55, 102779 | 8.8 | 14 |
| 105 | Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. *Lancet HIV,the*, **2021**, 8, e197-e205 | 7.8 | 14 |
| 104 | Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1. *Journal of Infectious Diseases*, **2018**, 218, 1523-1530 | 7 | 13 |

| | | | |
|---|---|---|---|
| 103 | Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults. *Journal of Infectious Diseases*, **2018**, 218, 1531-1540 | 7 | 13 |
| 102 | Epidemiological trends of HIV infection in Spain. *Aids*, **2002**, 16, 2496-2499 | 3.5 | 13 |
| 101 | Community-Onset Bloodstream and Other Infections, Caused by Carbapenemase-Producing : Epidemiological, Microbiological, and Clinical Features. *Open Forum Infectious Diseases*, **2016**, 3, ofw136 | 1 | 13 |
| 100 | Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. *Thorax*, **2021**, 76, 920-929 | 7.3 | 12 |
| 99 | No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial. *PLoS ONE*, **2014**, 9, e109718 | 3.7 | 11 |
| 98 | Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). *Current Opinion in HIV and AIDS*, **2009**, 4, 507-12 | 4.2 | 11 |
| 97 | Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. *HIV Clinical Trials*, **2017**, 18, 118-125 | | 11 |
| 96 | Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons. *Epidemiology*, **2020**, 31, e49-e51 | 3.1 | 11 |
| 95 | Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. *Antiviral Therapy*, **2009**, 14, 195-201 | 1.6 | 11 |
| 94 | Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2017**, 76, 102-109 | 3.1 | 10 |
| 93 | Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. *Patient*, **2015**, 8, 445-54 | 3.7 | 10 |
| 92 | New Strategies of ARV: the Road to Simplification. *Current HIV/AIDS Reports*, **2018**, 15, 11-19 | 5.9 | 10 |
| 91 | Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. *Enfermedades Infecciosas Y Microbiología Clínica*, **2016**, 34, 361-71 | 0.9 | 10 |
| 90 | Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). *Enfermedades Infecciosas Y Microbiología Clínica*, **2014**, 32, 447-58 | 0.9 | 10 |
| 89 | Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 65, 82-6 | 3.1 | 10 |
| 88 | Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy. *Annals of Internal Medicine*, **2000**, 132, 1011 | 8 | 10 |
| 87 | Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial. *Aids*, **2016**, 30, 75-82 | 3.5 | 10 |
| 86 | Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study. *BMC Infectious Diseases*, **2014**, 14, 379 | 4 | 9 |

| | | | |
|---|---|---|---|
| 85 | No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues. *AIDS Research and Human Retroviruses*, **2012**, 28, 1167-9 | 1.6 | 9 |
| 84 | Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial. *International Journal of STD and AIDS*, **2013**, 24, 679-81 | 1.4 | 9 |
| 83 | Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2008**, 48, 455-9 | 3.1 | 9 |
| 82 | The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens. *Journal of Antimicrobial Chemotherapy*, **2004**, 54, 587-92 | 5.1 | 9 |
| 81 | Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. *Clinical Microbiology and Infection*, **2021**, 27, 1678-1684 | 9.5 | 8 |
| 80 | Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 738-742 | 5.1 | 8 |
| 79 | Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial. *Clinical Infectious Diseases*, **2019**, 68, 1184-1192 | 11.6 | 7 |
| 78 | Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy. *Journal of the International AIDS Society*, **2014**, 17, 19578 | 5.4 | 7 |
| 77 | Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing. *Diagnostic Microbiology and Infectious Disease*, **2012**, 72, 90-6 | 2.9 | 7 |
| 76 | Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial. *Aids*, **2011**, 25, 393-4 | 3.5 | 7 |
| 75 | Influenza A pandemic (H1N1) 2009 virus and HIV. *Emerging Infectious Diseases*, **2010**, 16, 1175-6 | 10.2 | 7 |
| 74 | Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). *Enfermedades Infecciosas Y Microbiología Clínica*, **2019**, 37, 195-202 | 0.9 | 7 |
| 73 | Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. *Enfermedades Infecciosas Y Microbiología Clínica*, **2016**, 34, 516.e1-516.e18 | 0.9 | 6 |
| 72 | Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study. *Journal of NeuroVirology*, **2014**, 20, 362-70 | 3.9 | 6 |
| 71 | Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. *Enfermedades Infecciosas Y Microbiología Clínica*, **2017**, 35, 88-99 | 0.9 | 6 |
| 70 | Protease inhibitor monotherapy: what is its role?. *Current HIV/AIDS Reports*, **2012**, 9, 179-85 | 5.9 | 6 |
| 69 | A safety evaluation of raltegravir for the treatment of HIV. *Expert Opinion on Drug Safety*, **2018**, 17, 217-223 | 4.2 | 6 |
| 68 | Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. *AIDS Research and Human Retroviruses*, **2017**, 33, 29-32 | 1.6 | 5 |

| | | | |
|---|---|---|---|
| 67 | Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. *Enfermedades Infecciosas Y Microbiología Clínica*, **2018**, 36, 268-276 | 0.9 | 5 |
| 66 | Brief Report: Differential Effects of Tenofovir, Abacavir, Emtricitabine, and Darunavir on Telomerase Activity In Vitro. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2017**, 74, 91-94 | 3.1 | 5 |
| 65 | Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 1804-6 | 5.1 | 5 |
| 64 | Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 628-639 | 5.1 | 5 |
| 63 | Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease. *Journal of Infectious Diseases*, **2018**, 218, S574-S581 | 7 | 5 |
| 62 | Proof-of-concept trial of the combination of lactitol with and for the eradication of intestinal OXA-48-producing. *Gut Pathogens*, **2020**, 12, 15 | 5.4 | 4 |
| 61 | Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. *Enfermedades Infecciosas Y Microbiología Clínica*, **2019**, 37, 151-159 | 0.9 | 4 |
| 60 | FLAMINGO: how much rosier can antiretroviral therapy get?. *Lancet, The*, **2014**, 383, 2191-3 | 40 | 4 |
| 59 | A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 67, 419-23 | 3.1 | 4 |
| 58 | Noninferiority and lopinavir/ritonavir monotherapy trials. *Aids*, **2008**, 22, 1696-7 | 3.5 | 4 |
| 57 | Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2007**, 46, 118; author reply 118-9 | 3.1 | 4 |
| 56 | A new murine model of severe acute toxoplasma encephalitis. *Journal of Antimicrobial Chemotherapy*, **1995**, 36, 503-12 | 5.1 | 4 |
| 55 | Neuropatogénesis inducida por el virus del sida: estrategias terapéuticas frente a la neurodegeneración inducida por la glucoproteína gp120/Tat en el sistema nervioso central. *Revista De Neurologia*, **2011**, 52, 101 | 24 | 4 |
| 54 | Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 466-472 | 5.1 | 3 |
| 53 | Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis. *Journal of the International AIDS Society*, **2014**, 17, 19805 | 5.4 | 3 |
| 52 | Updating Our Understanding of Pulmonary Disease Associated With HIV Infection. *Archivos De Bronconeumologia*, **2012**, 48, 126-132 | 0.7 | 3 |
| 51 | Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases. *Malaria Journal*, **2012**, 11, 136 | 3.6 | 3 |
| 50 | Updating our understanding of pulmonary disease associated with HIV infection. *Archivos De Bronconeumologia*, **2012**, 48, 126-32 | 0.7 | 3 |

| | | | |
|---|---|---|---|
| 49 | Neurocognitive disorders during antiretroviral treatment, despite full HIV RNA suppression. *HIV Therapy*, **2010**, 4, 257-260 | | 3 |
| 48 | Prevenci□ de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH. Recomendaciones de GESIDA/Plan Nacional sobre el Sida. A□ 2003. *Enfermedades Infecciosas Y Microbiologí□ Clí□nica*, **2004**, 22, 160-176 | 0.9 | 3 |
| 47 | Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit. *Travel Medicine and Infectious Disease*, **2020**, 33, 101543 | 8.4 | 3 |
| 46 | Longitudinal changes in epigenetic age acceleration in aviremic HIV-infected recipients of long-term antiretroviral treatment. *Journal of Infectious Diseases*, **2021**, | 7 | 3 |
| 45 | Presenting characteristics and outcomes of migrants in a cohort of hospitalized patients with COVID-19: Does the origin matter?. *Travel Medicine and Infectious Disease*, **2021**, 42, 102027 | 8.4 | 3 |
| 44 | Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals. *PLoS ONE*, **2020**, 15, e0230772 | 3.7 | 3 |
| 43 | Therapeutic management of Crimean-Congo haemorrhagic fever. *Enfermedades Infecciosas Y Microbiologí□ Clí□nica*, **2018**, 36, 517-522 | 0.9 | 2 |
| 42 | Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2018**, 77, 102-109 | 3.1 | 2 |
| 41 | Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance. *Aids*, **2014**, 28, 932-4 | 3.5 | 2 |
| 40 | Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study. *Journal of the International AIDS Society*, **2014**, 17, 19554 | 5.4 | 2 |
| 39 | Facial emotional processing deficits in long-term HIV-suppressed patients. *Journal of the International AIDS Society*, **2014**, 17, 19664 | 5.4 | 2 |
| 38 | Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?. *Aids*, **2013**, 27, 141-4 | 3.5 | 2 |
| 37 | Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]. *Enfermedades Infecciosas Y Microbiologí□ Clí□nica*, **2004**, 22, 160-76 | 0.9 | 2 |
| 36 | Comparison of NNRTIs in antiretroviral-na□ve patients. *International Journal of STD and AIDS*, **2001**, 12 Suppl 4, 3-9 | 1.4 | 2 |
| 35 | Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. *Annals of Internal Medicine*, **2021**, 174, 581-582 | 8 | 2 |
| 34 | Critical Care Requirements Under Uncontrolled Transmission of SARS-CoV-2. *American Journal of Public Health*, **2021**, 111, 923-926 | 5.1 | 2 |
| 33 | Risks and benefits of reducing the number of drugs to treat HIV-1 infection. *Expert Opinion on Drug Safety*, **2021**, 20, 397-409 | 4.1 | 2 |
| 32 | COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. *HIV Medicine*, **2021**, 22, 867-876 | 2.7 | 2 |

| | | | |
|---|---|---|---|
| 31 | Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. *Aids*, **2022**, 36, 39-48 | 3.5 | 2 |
| 30 | Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial.. *Journal of Clinical Medicine*, **2022**, 11, | 5.1 | 2 |
| 29 | Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. *Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )*, **2019**, 37, 151-159 | 0.1 | 1 |
| 28 | Autochthonous Crimean-Congo haemorrhagic fever in Spain: So much to learn. *Enfermedades Infecciosas Y Microbiologí Clínica*, **2018**, 36, 202 | 0.9 | 1 |
| 27 | Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid. *Open Forum Infectious Diseases*, **2016**, 3, ofw041 | 1 | 1 |
| 26 | Estudio farmacoeconómico de lopinavir/ritonavir en monoterapia en el ensayo clínico OK04. *Pharmacoeconomics - Spanish Research Articles*, **2011**, 8, 85-98 | | 1 |
| 25 | Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions. *BMC Infectious Diseases*, **2008**, 8, 20 | 4 | 1 |
| 24 | Treatment of advanced HIV infection. *Journal of Antimicrobial Chemotherapy*, **2003**, 51, 225-7 | 5.1 | 1 |
| 23 | Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort.. *Biomedicine and Pharmacotherapy*, **2021**, 146, 112572 | 7.5 | 1 |
| 22 | Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. *Infectious Diseases and Therapy*, **2021**, 1 | 6.2 | 1 |
| 21 | Absence of IgG antibodies among high-risk contacts of two confirmed cases of Crimean-Congo haemorrhagic fever in the autonomous region of Madrid (Spain). *Journal of Infection and Public Health*, **2020**, 13, 1595-1598 | 7.4 | 1 |
| 20 | Ageing with HIV: Challenges and biomarkers.. *EBioMedicine*, **2022**, 77, 103896 | 8.8 | 1 |
| 19 | Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV.. *Aids*, **2022**, 36, 751-753 | 3.5 | 1 |
| 18 | Therapeutic management of Crimean-Congo haemorrhagic fever. *Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )*, **2018**, 36, 517-522 | 0.1 | 0 |
| 17 | Health Care Workers' Reasons for Choosing Between Two Different COVID-19 Prophylaxis Trials in an Acute Pandemic Context: Single-Center Questionnaire Study. *Journal of Medical Internet Research*, **2021**, 23, e23441 | 7.6 | 0 |
| 16 | Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study). *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 3263-3271 | 5.1 | 0 |
| 15 | Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. *Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )*, **2017**, 35, 88-99 | 0.1 | |
| 14 | P045 Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults. *Sexually Transmitted Infections*, **2016**, 92, A34.1-A34 | 3.8 | |

| | | |
|---|---|---|
| 13 | Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function. *Enfermedades Infecciosas Y Microbiologa Clnica*, **2016**, 34, 29-32 | 0.9 |
| 12 | Autochthonous Crimean-Congo haemorrhagic fever in Spain: So much to learn. *Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )*, **2018**, 36, 202 | 0.1 |
| 11 | Antiviral Therapy **2017**, 918-926.e1 | |
| 10 | Second-line antiretroviral therapy and the human factor. *Lancet HIV,the*, **2015**, 2, e34-5 | 7.8 |
| 9 | Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials. *Journal of the International AIDS Society*, **2014**, 17, 19807 | 5.4 |
| 8 | Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults. *Journal of the International AIDS Society*, **2014**, 17, 19603 | 5.4 |
| 7 | A benchmark for management of drug resistant HIV. *Lancet Infectious Diseases, The*, **2013**, 13, 561-2 | 25.5 |
| 6 | Incorrect attribution of cerebrospinal fluid HIV-1 virological escape and lymphocytic meningitis to lopinavir/ritonavir monotherapy. *Aids*, **2010**, 24, 2415-6 | 3.5 |
| 5 | Response to: Assessment of Baseline HIV Viral Load as a Risk Factor for Loss of Virologic Suppression in Protease Inhibitor-Based Monotherapy Trials *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2010**, 53, 670 | 3.1 |
| 4 | Nuevas dianas y nuevos fmacos en el tratamiento de la infecci por el VIH. *Enfermedades Infecciosas Y Microbiologa Clnica*, **2005**, 23, 25-32 | 0.9 |
| 3 | Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone. *American Journal of Tropical Medicine and Hygiene*, **2020**, 103, 1480-1486 | 3.2 |
| 2 | Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. *AIDS Research and Therapy*, **2020**, 17, 45 | 3 |
| 1 | Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort.. *Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )*, **2022**, 40, 121-124 | 0.1 |